Mylan and its partner Biocon have received a Complete Response Letter from the FDA in regard to their application for a follow-on insulin glargine referencing Lantus.
Mylan and its partner Biocon have received a Complete Response Letter (CRL) from the FDA in regard to their application for a follow-on insulin glargine referencing Lantus.
Though neither Mylan nor Biocon have issued corporate statements concerning the CRL, Julie Knell, senior director of global product communications for Mylan, acknowledged the CRL in an email to The Center for Biosimilars®, and said that, “Following submission of our Insulin Glargine application under the 505(b)(2) regulatory pathway, we had agreed with FDA to provide additional clinical data in support of the manufacturing site change from Bangalore to Malaysia. Hence, the recent CRL was anticipated and built into our plan."
Knell continued, “Together, Mylan and Biocon are already executing on all required activities we had agreed upon with FDA, and they are progressing according to plan,” and said that the companies did not anticipate a change of timing for their anticipated launch.
The CRL comes after Biocon received a Form 483 from the FDA in February that noted 6 observations after an inspection of a manufacturing facility in Malaysia revealed conditions that may have violated the Food Drug and Cosmetic Act.
In contrast with the FDA's concerns, regulatory agencies in Europe and Australia have both authorized the drug. In March 2018, the product was authorized for marketing as a biosimilar by both the European Commission, following a positive opinion from the Committee for Medicinal Products for Human Use in January 2018, as well as by the Therapeutic Goods Administration of Australia. The biosimilar will be sold under the brand name Semglee in a 100 IU/mL 3mL prefilled pen in both territories.
This CRL is the latest in a series from the FDA for proposed follow-on and biosimilar products. In the last 2 months, Amgen received a CRL for its proposed trastuzumab biosimilar, ABP 980; Pfizer received a CRL for its proposed trastuzumab biosimilar, PF-05280014; and Celltrion received CRLs for its proposed rituximab and trastuzumab biosimilars CT-P10, and CT-P6, respectively.
BioRationality: MHRA's Procedure Enables Automatic Registration of Biosimilars Approved Elsewhere
March 18th 2024Sarfaraz K. Niazi, PhD, explains how the new international regognition procedure under the Medicines and Healthcare products Regulatory Agency (MHRA) could expand biosimilar access within the United kingdom, in his latest column.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
Coherus Biosciences Cites Biosimilars as Main Drivers of 2023 Revenue Growth
March 14th 2024In its earnings report for the fourth quarter and full year of 2023, Coherus Biosciences detailed its rising revenue growth, which it partly attributed to increased sales for its pegfilgrastim and ranibizumab biosimilars.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
FDA Green Lights Second Tocilizumab Biosimilar
March 7th 2024The FDA has approved Fresenius Kabi's tocilizumab biosimilar (Tyenne; tocilizumab-aazg), making it the second tocilizumab biosimilar overall and first tocilizumab biosimilar to be approved with both intravenous and subcutaneous administration options.
Eye on Pharma: Canadian Aflibercept Settlement; Sandoz Acquires Cimerli; Payer Chooses Cyltezo
March 6th 2024Biocon Biologics settled with the maker of Eylea (aflibercept), announcing a launch date for its biosimilar competitor in Canada; Sandoz has officially acquired Cimerli, a ranibizumab biosimilar; AARP Medicare Rx from United Healthcare has added Cyltezo (adalimumab-adbm) and removed the originator (Humira) from its formulary.